These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 35632758)

  • 1. Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.
    Zheng X; Huang Y; Li K; Luo R; Cai M; Yun J
    Viruses; 2022 May; 14(5):. PubMed ID: 35632758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond Viral Infections: The Multifaceted Roles of Human Papillomavirus and Epstein-Barr Virus in Shaping the Tumor Microenvironment.
    Fernandes Q; Sher G; Prabhu KS; Kuttikrishnan S; Merhi M; Dermime S; Junejo K; Bhat AA; Uddin S
    Discov Med; 2024 Jan; 36(180):1-15. PubMed ID: 38273742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
    Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
    Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Microenvironment in Epstein-Barr Virus-Associated Malignancies.
    Tan GW; Visser L; Tan LP; van den Berg A; Diepstra A
    Pathogens; 2018 Apr; 7(2):. PubMed ID: 29652813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.
    Lei Y; Cao P; Zheng X; Wei J; Cheng M; Liu M
    Cancer Med; 2023 Oct; 12(19):19838-19849. PubMed ID: 37732493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune escape mechanism of nasopharyngeal carcinoma.
    Li X; Guo Y; Xiao M; Zhang W
    FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape.
    Salnikov MY; MacNeil KM; Mymryk JS
    Front Immunol; 2024; 15():1358511. PubMed ID: 38596668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy.
    Zhang B; Choi IK
    Clin Cancer Res; 2022 Oct; 28(20):4363-4369. PubMed ID: 35686929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Evasion by Epstein-Barr Virus.
    Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
    Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy for EBV-associated malignancies.
    Gottschalk S; Heslop HE; Rooney CM
    Leuk Lymphoma; 2005 Jan; 46(1):1-10. PubMed ID: 15621775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics.
    Tao Q; Young LS; Woodman CB; Murray PG
    Front Biosci; 2006 Sep; 11():2672-713. PubMed ID: 16720343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas.
    Zhou H; Jing S; Liu Y; Wang X; Duan X; Xiong W; Li R; Peng Y; Ai Y; Fu D; Wang H; Zhu Y; Zeng Z; He Y; Ye Q
    Cell Prolif; 2023 Mar; 56(3):e13373. PubMed ID: 36519208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic regulation of the tumour and its microenvironment: The role of Epstein-Barr virus.
    Lee SH; Khoo AS; Griffiths JR; Mat Lazim N
    Int J Cancer; 2025 Feb; 156(3):488-498. PubMed ID: 39291683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
    J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment and RIG-I signaling molecules in Epstein Barr virus-positive and -negative classical Hodgkin lymphoma of the elderly.
    Satoh T; Wada R; Yajima N; Imaizumi T; Yagihashi S
    J Clin Exp Hematop; 2014; 54(1):75-84. PubMed ID: 24942949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
    Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
    mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
    Dasari V; Sinha D; Neller MA; Smith C; Khanna R
    Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments.
    Shechter O; Sausen DG; Gallo ES; Dahari H; Borenstein R
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
    Nagpal P; Descalzi-Montoya DB; Lodhi N
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PD-L1 in EBV-associated malignancies.
    Li X; Zhang W
    Int Immunopharmacol; 2021 Jun; 95():107553. PubMed ID: 33765613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.